Joe Allen Credit Illustration by Andy Friedman

The New Yorker - 6 days ago
Allen's empire expanded to...

Bill would expand access to medical pot in Iowa

Quad City Times - 4 weeks ago
The expanded medical conditions...

'Right to Try Act' gives hope to dying patients

Minneapolis Star Tribune - 2 weeks ago
Linda Griffiths' ALS regularly...

Legislation to let terminally ill people try experimental drugs is debated

Chicago Tribune - 3 weeks ago
The proposals seek to circumvent...

CT bill would provide access to unapproved drugs

Yale Daily News (blog) - 3 weeks ago
Debra Gove of Durham, Conn....

Axway und ING: Webinar zum Thema Datentransfer im digitalen Geschäftsumfeld

SYS-CON Media (press release) - 2 days ago
Seit mehr als einem Jahrzehnt...

Move over, Reddit: Tumblr is the new front page of the Internet.

Washington Post - 2 weeks ago
Since December, when Tumblr...

Another state considers terminally ill access to experimental drugs

McKnight's Long Term Care News - 3 weeks ago
Advocates, including the AIDS...

Oklahoma Right to Try Act expands access to experimental drugs, devices for ...

The Republic - 1 month ago
Harada was accepted into a...

Viscount Options Cherry Creek Property to Sumitomo

Yahoo Finance UK - 4 weeks ago
Samples were submitted to the ALS...

News via Google. See more news matching 'als expanded access'

 

Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.